These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. [Bone and hormones. Effects of growth hormone on bone tissue in adults]. Chapurlat RD; Delmas PD Presse Med; 1999 Mar; 28(10):559-62. PubMed ID: 10209550 [TBL] [Abstract][Full Text] [Related]
45. Promising new agents in osteoporosis. Reginster JY; Henrotin Y; Gosset C Drugs R D; 1999 Mar; 1(3):195-201. PubMed ID: 10566024 [TBL] [Abstract][Full Text] [Related]
46. Rationale for using nitric oxide donor therapy for prevention of bone loss and treatment of osteoporosis in humans. Wimalawansa SJ Ann N Y Acad Sci; 2007 Nov; 1117():283-97. PubMed ID: 18056048 [TBL] [Abstract][Full Text] [Related]
47. The role of calcitonin in the development and treatment of osteoporosis. McDermott MT; Kidd GS Endocr Rev; 1987 Nov; 8(4):377-90. PubMed ID: 3319529 [TBL] [Abstract][Full Text] [Related]
49. GH/IGF-I and bone resorption in vivo and in vitro. Ueland T Eur J Endocrinol; 2005 Mar; 152(3):327-32. PubMed ID: 15757846 [TBL] [Abstract][Full Text] [Related]
50. Growth hormone and insulin-like growth factors as anabolic therapies for osteoporosis. Eriksen EF; Kassem M; Brixen K Horm Res; 1993; 40(1-3):95-8. PubMed ID: 8300056 [TBL] [Abstract][Full Text] [Related]
51. L-arginine prevents heart transplant arteriosclerosis by modulating the vascular cell proliferative response to insulin-like growth factor-I and interleukin-6. Lou H; Kodama T; Wang YN; Katz N; Ramwell P; Foegh ML J Heart Lung Transplant; 1996 Dec; 15(12):1248-57. PubMed ID: 8981210 [TBL] [Abstract][Full Text] [Related]
52. Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment. Gennari C; Nuti R; Agnusdei D; Camporeale A; Martini G Drug Saf; 1994 Sep; 11(3):179-95. PubMed ID: 7811400 [TBL] [Abstract][Full Text] [Related]
53. Prevention of bone loss after ovariectomy in mice with preferential overexpression of the transcription factor paired box-5 in osteoblasts. Fujita H; Hinoi E; Watanabe T; Iezaki T; Takamori M; Ogawa S; Yoneda Y Biol Pharm Bull; 2013; 36(3):481-4. PubMed ID: 23449333 [TBL] [Abstract][Full Text] [Related]
54. [Osteoporosis treatment in patients with hyperthyroidism]. Saito J; Nishikawa T Nihon Rinsho; 2009 May; 67(5):1011-6. PubMed ID: 19432125 [TBL] [Abstract][Full Text] [Related]
55. Role of growth hormone and sex steroids in achieving and maintaining normal bone mass. Holmes SJ; Shalet SM Horm Res; 1996; 45(1-2):86-93. PubMed ID: 8742125 [TBL] [Abstract][Full Text] [Related]
56. Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products. Bonjour JP; Kohrt W; Levasseur R; Warren M; Whiting S; Kraenzlin M Nutr Res Rev; 2014 Dec; 27(2):252-67. PubMed ID: 25394580 [TBL] [Abstract][Full Text] [Related]
57. Short-term effects of growth hormone and insulin-like growth factor I on cancellous bone in rhesus macaque monkeys. Sass DA; Jerome CP; Bowman AR; Bennett-Cain A; Ginn TA; LeRoith D; Epstein S J Clin Endocrinol Metab; 1997 Apr; 82(4):1202-9. PubMed ID: 9100597 [TBL] [Abstract][Full Text] [Related]
58. Oral L-arginine before resistance exercise blunts growth hormone in strength trained males. Forbes SC; Harber V; Bell GJ Int J Sport Nutr Exerc Metab; 2014 Apr; 24(2):236-44. PubMed ID: 24225560 [TBL] [Abstract][Full Text] [Related]
59. Mechanisms of glucocorticoid action in bone cells. Delany AM; Dong Y; Canalis E J Cell Biochem; 1994 Nov; 56(3):295-302. PubMed ID: 7876321 [TBL] [Abstract][Full Text] [Related]
60. Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidronate: a placebo controlled trial. Erdtsieck RJ; Pols HA; Valk NK; van Ouwerkerk BM; Lamberts SW; Mulder P; Birkenhäger JC Clin Endocrinol (Oxf); 1995 Nov; 43(5):557-65. PubMed ID: 8548940 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]